The ongoing NV-CoV-2 Phase Ia clinical study is a key milestone in the development of Nanoviricides' (NV) novel and innovative anti-virus therapy, NV-CoV-2 uses a sophisticated polymer (NV-387) as the active ingredient to trap and disrupt viruses in the blood. The therapy aims to reduce the viral load to prevent infection of healthy cells and to enable the immune system to clear viruses rapidly.NV has announced that its recruitment of 36 volunteers (18 active, 18 placebo) is going well with 72% (26/36) having received a single dose. No side effects are reported. Three dose levels are being tested. The design is shown in Exhibit 1.
